Quotables
"If you build a better mousetrap, you will catch better mice."
George Gobel
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8025865 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 09/27/2011 |
| 8012707 | MN gene and protein A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenic... | 09/06/2011 |
| 7993852 | MN/CA IX and cancer prognosis Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary o... | 08/09/2011 |
| 7981692 | Immunoassays to detect diseases or disease susceptibility traits Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gen... | 07/19/2011 |
| 7910691 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 03/22/2011 |
| 7910549 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 03/22/2011 |
| 7846673 | Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a ... | 12/07/2010 |
| 7867717 | Immunoassays to detect diseases or disease susceptibility traits Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gen... | 01/11/2011 |
| 7855185 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 12/21/2010 |
| 7851455 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 12/14/2010 |
| 7838240 | MN/CA IX/CA9 and renal cancer prognosis Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene... | 11/23/2010 |
| 7833739 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833738 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833737 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833734 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833728 | Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) in body fluids, such as, urine and serum. Said s-CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteog... | 11/16/2010 |
| 7833514 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7829065 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably membrane-impermeant compounds, which inhibit the enzymati... | 11/09/2010 |
| 7820159 | MN/CA IX and EGFR pathway inhibition The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with ... | 10/26/2010 |
| 7816496 | MN gene and protein A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenic... | 10/19/2010 |
| 7816493 | Soluble form of carbonic anhydrase IX (S-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/NEU/C-ERBB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a ... | 10/19/2010 |
| 7741048 | MN/CA IX and cancer prognosis Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary o... | 06/22/2010 |
| 7713704 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 05/11/2010 |
| 7550424 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably membrane-impermeant compounds, which inhibit the enzymati... | 06/23/2009 |
| 7482129 | MN/CA IX/CA9 and Renal Cancer Prognosis Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene... | 01/27/2009 |
| 7282345 | C-erbB-2 external domain: GP75 Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quant... | 10/16/2007 |
| 7186514 | MN gene and protein A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenic... | 03/06/2007 |
| 7148016 | Immunoassays to detect diseases or disease susceptibility traits Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gen... | 12/12/2006 |
| 7115715 | Anti-idiotype antibodies to MN proteins and MN polypeptides Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN g... | 10/03/2006 |
| 6774117 | MN gene and protein A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenic... | 08/10/2004 |
| 6297051 | MN gene and protein Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such ab... | 10/02/2001 |
| 6297041 | MN gene and protein Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such ab... | 10/02/2001 |
| 6204370 | MN gene and protein A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tu... | 03/20/2001 |
| 6069242 | MN gene and protein A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tu... | 05/30/2000 |
| 6025149 | Urinary screening for down syndrome and other aneuploidies This invention represents a significant advance in prenatal diagnosis by providing urinary screening to detect fetal aneuploidies. Herein disclosed are methods for prenatally assessing risks of a pregnancy being affected by Down syndrome and other aneuplo... | 02/15/2000 |
| 5708161 | Nucleoside phosphorothioate derivatives, synthesis and use thereof Inter alia, a process for the production of a nucleoside phosphorothioate derivative corresponding to the following general formula (I): ##STR1## characterized in that it comprises reacting a salt of a nucleoside H-phosphonate corresponding to the fo... | 01/13/1998 |
| 5516598 | Secondary cell using organosulfur/metal charge transfer materials as positive electrode A novel battery cell is disclosed which is characterized by a metal-organosulfur positive electrode which has one or more metal-sulfur bonds wherein when the positive electrode is charged and discharged, the formal oxidation state of the metal is changed.... | 05/14/1996 |
| 5395767 | Gene for ataxia-telangiectasia complementation group D (ATDC) Disclosed herein is a new gene, an AT gene for complementation group D, the ATDC gene and fragments thereof. Nucleic acid probes for said gene are provided as well as proteins encoded by said gene, cDNA therefrom, preferably a 3 kilobase (kb) cDNA, and re... | 03/07/1995 |
| 4802912 | Herbicide antidotes This invention relates to haloalkyl-sulfenoxyl-2, 3-dibromopropane compounds and their use as antidotes for thiocarbamate herbicides.... | 02/07/1989 |
| 4762548 | Herbicide compositions of extended soil life Herbicidally active thiolcarbamates are employed in combination with a certain amide extender compound, the latter in sufficient quantity to minimize soil degradation and to prolong the soil life of the former. As a result, the herbicidal effectiveness of... | 08/09/1988 |
